Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Moodys
Express Scripts
Harvard Business School
AstraZeneca

Last Updated: January 26, 2023

CLINICAL TRIALS PROFILE FOR PHENTERMINE HYDROCHLORIDE; TOPIRAMATE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Phentermine Hydrochloride; Topiramate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00518466 ↗ Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults Completed VIVUS, Inc. Phase 1 2007-07-01 The primary objective of this study is to describe the single- and multiple-dose pharmacokinetic profiles of two novel formulations of topiramate and commercially available immediate release topiramate, all dosed with immediate release phentermine.
NCT00563368 ↗ A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults Completed Medpace, Inc. Phase 3 2007-12-01 The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose. This study will provide confirmatory data to demonstrate that doses of VI-0521 have efficacy that is greater than placebo and each of the single-agent components that comprise the combination dose.
NCT00563368 ↗ A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults Completed VIVUS, Inc. Phase 3 2007-12-01 The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose. This study will provide confirmatory data to demonstrate that doses of VI-0521 have efficacy that is greater than placebo and each of the single-agent components that comprise the combination dose.
NCT00600067 ↗ A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults Completed Sentrx Phase 2 2008-01-01 The purpose of the study is to determine the long-term safety and efficacy of VI-0521 (phentermine/topiramate) compared to placebo in providing blood sugar control in Type 2 diabetic adults. Continuation of initial 6 month trial.
NCT00600067 ↗ A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults Completed Synteract, Inc. Phase 2 2008-01-01 The purpose of the study is to determine the long-term safety and efficacy of VI-0521 (phentermine/topiramate) compared to placebo in providing blood sugar control in Type 2 diabetic adults. Continuation of initial 6 month trial.
NCT00600067 ↗ A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults Completed VIVUS, Inc. Phase 2 2008-01-01 The purpose of the study is to determine the long-term safety and efficacy of VI-0521 (phentermine/topiramate) compared to placebo in providing blood sugar control in Type 2 diabetic adults. Continuation of initial 6 month trial.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Phentermine Hydrochloride; Topiramate

Condition Name

Condition Name for Phentermine Hydrochloride; Topiramate
Intervention Trials
Obesity 13
Diabetes 2
Binge Eating Disorder 2
Polycystic Ovary Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Phentermine Hydrochloride; Topiramate
Intervention Trials
Obesity 14
Overweight 4
Pediatric Obesity 3
Obesity, Morbid 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Phentermine Hydrochloride; Topiramate

Trials by Country

Trials by Country for Phentermine Hydrochloride; Topiramate
Location Trials
United States 31
Mexico 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Phentermine Hydrochloride; Topiramate
Location Trials
California 6
Minnesota 5
Ohio 3
Colorado 2
Florida 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Phentermine Hydrochloride; Topiramate

Clinical Trial Phase

Clinical Trial Phase for Phentermine Hydrochloride; Topiramate
Clinical Trial Phase Trials
Phase 4 5
Phase 3 4
Phase 2 9
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Phentermine Hydrochloride; Topiramate
Clinical Trial Phase Trials
Completed 11
Recruiting 8
Terminated 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Phentermine Hydrochloride; Topiramate

Sponsor Name

Sponsor Name for Phentermine Hydrochloride; Topiramate
Sponsor Trials
VIVUS, Inc. 7
University of Minnesota 4
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Phentermine Hydrochloride; Topiramate
Sponsor Trials
Other 23
Industry 14
NIH 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
McKinsey
Colorcon
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.